[HTML][HTML] RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre, A Brugarolas - BMC cancer, 2021 - Springer
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre… - BMC …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
[HTML][HTML] RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre, A Brugarolas - BMC Cancer, 2021 - ncbi.nlm.nih.gov
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
RG Manzano, A Catalan-Latorre, A Brugarolas - BMC Cancer, 2021 - go.gale.com
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
RG Manzano, A Catalan-Latorre, A Brugarolas - BMC Cancer, 2021 - europepmc.org
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
[PDF][PDF] RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre, A Brugarolas - 2021 - scholar.archive.org
Background: Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
[HTML][HTML] RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre… - BMC …, 2021 - bmccancer.biomedcentral.com
Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic
alterations in a variable percentage of tumors throughout all molecular subtypes. MIBCs with …
alterations in a variable percentage of tumors throughout all molecular subtypes. MIBCs with …
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
RG Manzano, A Catalan-Latorre… - BMC Cancer, 2021 - search.ebscohost.com
Abstract < bold> Background: </bold> Muscle invasive urothelial bladder
carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of …
carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of …
[引用][C] RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre… - BMC Cancer (Web), 2021 - jglobal.jst.go.jp
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to
immunity checkpoint inhibitors in urothelial bladder cancer | Article Information | J-GLOBAL …
immunity checkpoint inhibitors in urothelial bladder cancer | Article Information | J-GLOBAL …
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer
RG Manzano, A Catalan-Latorre, A Brugarolas - BMC Cancer, 2021 - search.proquest.com
Background Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …
somatic alterations in a variable percentage of tumors throughout all molecular subtypes …